Table 1. Case series of non-diabetic metabolic nodular glomerulosclerosis – clinical characteristics.
| Markowitz et al. (2002) [3] | Li and Verani (2008) [9] | Wu et al. (2013) [7] | Salvatore et al. (2015) [8] | Hamrahian et al. (2018) [10] | |
|---|---|---|---|---|---|
| Number of patients | 23 | 15 | 20 | 4* | 17 |
| Male, % | 78 | 33 | 80 | 100 | 76 |
| Race | |||||
| White, % | 74 | 73 | 100 | 41 | |
| Black, % | 26 | 20 | 0 | 41 | |
| Asian, % | 0 | 0 | 0 | 6 | |
| Hispanic, % | 0 | 7 | 0 | 6 | |
| Media age, years (min – max) | 68 (47 – 80) | 64 (48 – 76) | 56 (16 – 71) | 62 (48 – 72) | 60 (27 – 81) |
| Hypertension, % | 96 | 93 | 90 | 100 | 100 |
| Duration of hypertension, years | 15 | 14 | 4 | ||
| Smokers, % | 91 | 67 | 85 | 100 | 65 |
| Cumulative cigarette intake, pack-years | 53 | 54 | 20 | 23 years | |
| Obesity (BMI > 30), % | 13 | 60 | 55 | 35 | |
| Overweight (BMI 25 – 29), % | 27 | 40 | 35 | ||
| Hypercholesterolemia, % | 90 | 50 | |||
| Median creatinine at the diagnosis, mg/dL (min – max) | 2.4 | 2.8 (1 – 6.8) | 4.2 (1.1 – 8) | 1.9 (1.3–3.0) | 2.35 |
| Median proteinuria, g/day (min – max) | 4.7 | 5.6 (1 – 11.3) | 2.85 (1.26 – 6.11) | 3.0 (1.75 – 5.5) | 3.58 g/g (0.8 – 12.3) |
| Nephrotic-range proteinuria, % | 70 | 73 | 35 | ||
| Nephrotic syndrome, % | 22 | 53 | |||
| Microhematuria, % | 75 | 25 | |||
| ESRD, % | 35 | 30 | 25 | ||
*Six patients were excluded for nodular glomerulosclerosis pattern absence. ESRD = end-stage renal disease.